Saint Priest

Researchers are investigating the use of psilocybin-assisted psychotherapy PAP to prevent relapse in adults with alcohol use disorder AUD who also experience depressive symptoms. This study compares the effects of high-dose versus low-dose psilocybin in reducing relapse risk over six months. The study builds on earlier pilot findings suggesting psilocybin may reduce drinking days and cravings, offering a potentially faster-acting option than traditional antidepressants for individuals with AUD and depression. Participants receive two doses of psilocybin, either a high dose of 25 mg or a low dose of 3 mg, administered three weeks apart. The study uses a randomized, parallel design, with participants assigned to either the high-dose or low-dose group to evaluate differences in relapse prevention. A third dose may be offered later based on participant request and study assessments. During the study, participants are closely monitored with scheduled assessments of drinking behavior, craving, depressive symptoms, anxiety, quality of life, and other psychological factors. Various tests and questionnaires are administered at baseline and multiple follow-up points up to 51 weeks. Safety and tolerance of psilocybin are also evaluated. The total participation duration extends to about one year, allowing detailed observation of relapse rates and related outcomes.

Researchers are conducting a phase 3, open-label, randomized study in adults aged 18 to 69 with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation ASCT and high-dose chemotherapy. The trial aims to evaluate the effectiveness and safety of using elranatamab and lenalidomide as alternatives to standard chemotherapy in the consolidation phase, and to compare elranatamab alone with standard maintenance therapies. This study involves about 824 patients across approximately 70 sites and addresses important outcomes like minimal residual disease MRD negativity, progression-free survival, and overall survival. Participants receive standard induction therapy with four cycles of D-VRd daratumumab, bortezomib, lenalidomide, dexamethasone followed by either ASCT and D-VRd consolidation standard arm or elranatamab with lenalidomide consolidation experimental arm. After consolidation, patients enter a maintenance phase where they are re-randomized to receive either daratumumab plus lenalidomide or elranatamab monotherapy for about two years. Treatment adjustments depend on MRD status and disease progression during maintenance. Throughout the study, participants undergo regular assessments including disease evaluations and safety monitoring. Researchers measure MRD negativity rates, progression-free survival, overall survival, adverse events, and quality of life using validated questionnaires. The trial offers long-term follow-up, lasting up to around 10 years, to capture comprehensive data on treatment effects and patient well-being.

Human papillomaviruses HPV are common contagious viruses, with about 70% of men and women expected to be infected during their lifetime. Despite vaccination recommendations since 2007 for girls and since 2021 for young people aged 11 to 14, vaccination rates remain low, especially in the Auvergne Rhne Alpes region. This regional study aims to evaluate the effect of a primary prevention program on increasing HPV vaccination rates among adolescents aged 11 to 17. The study compares two groups one receiving no intervention and the other receiving an HPV primary prevention intervention. The intervention includes a one-week interactive exhibition titled Taking care of yourself and preventing cancer risks, a classroom presentation on HPV delivered by a healthcare team, and distribution of prevention materials. The presentation features key information about HPV, its transmission, affected groups, possible consequences, and protection methods, including interactive discussions and games. Participants will be assessed at the start and six months later for HPV vaccination status, health literacy, and knowledge about HPV and cancer risks. Acceptability of the intervention is evaluated at the end of the one-week program. The study involves students and teachers at public middle and high schools, with follow-up over six months to monitor vaccination uptake and related knowledge improvements.

This research aims to improve preventive health practices in primary care by supporting changes in diet, physical activity, and sedentary behavior among adults. The study focuses on patients who are less motivated to change these behaviors and evaluates a tailored training program for general practitioners GPs in France. The goal is to enhance brief opportunistic interventions during routine consultations to reduce chronic condition risks linked to unhealthy behaviors. The study compares two groups one where GPs receive specialized training in Healthy Conversation Skills to support patients behavior change, and a control group where GPs continue usual care without this training. The training includes online courses, workshops, follow-up coaching, and patient support materials adapted from the Making Every Contact Count program. Trained GPs provide brief behavior change support during routine visits. Participants are adults registered with participating practices who have low motivation to change diet or exercise habits. Researchers will assess motivation to change behaviors using specific scales two weeks after consultation. The study monitors patients readiness to adopt healthier behaviors and gathers data on the programs implementation and effectiveness. Participation involves routine care visits and follow-up assessments, with the study running until July 2029.